PIK3CD and Hyperglycemia: Hyperglycemia is a known class effect of agents targeting the PI3K/AKT/mTOR signaling pathway [11] and was expected based on previous reports of other PI3K inhibitors [11–17] and the first-in-human study of copanlisib [10].